Exscientia has a total of 18 patents globally, out of which none have been granted. Of these 18 patents, more than 88% of patents are active. The United Kingdom is where Exscientia has filed the maximum number of patents, followed by Europe and Australia, it has generated annual revenue of $12.4 million in the year 2020. Parallelly, the UK seems to be the main focused R&D center and is also the origin country of Exscientia.
Exscientia was founded in the year 2012 by Andrew Hopkins. The company is a pharmatech business that designs and discovers new medications using an end-to-end AI platform. As of March 2022, Exscientia has a market cap of $1.73 Billion.
Do read about some of the most popular patents of Exscientia which have been covered by us in this article and also you can find Exscientia’s patents information, the worldwide patent filing activity, its patent filing trend over the years, and many other stats over Exscientia’s patent portfolio.
How many patents do the founder and the CEO of Exscientia have?
The founder and CEO, Andrew Hopkins, has 18 patents.
How many patents does Exscientia have?
Exscientia has a total of 18 patents globally. These patents belong to 10 unique patent families. Out of 18 patents, 16 patents are active.
How many Exscientia patents are Alive/Dead?
How Many Patents did Exscientia File Every Year?
Are you wondering why there is a drop in patent filing for the last two years? It is because a patent application can take up to 18 months to get published. Certainly, it doesn’t suggest a decrease in the patent filing.
|Year of Patents Filing or Grant||Exscientia Applications Filed||Exscientia Patents Granted|
How Many Patents did Exscientia File in Different Countries?
Where are Research Centres of Exscientia Patents Located?
Centaur AI, as well as AI pharma tech, are among the AI-focused drug design and discovery systems developed by Exscientia. The time-consuming process of drug discovery and design is substantially sped up with these technologies.
Their platform demonstrated for the first time in a prospective interventional trial that functional precision-oncology can improve patient outcomes in the landmark EXALT1 clinical study.
EXALT1 is the world’s first prospective interventional study. Based on testing drug reactions ex vivo in patients’ own tissue samples, the platform’s predictions suggested which therapy would be most beneficial for late-stage hematological cancer patients.
Exscientia has delivered its first two AI-designed medicinal compounds to clinical trials, the first for Alzheimer’s disease symptoms and the second for cancer immunotherapy, in collaboration with Sumitomo Dainippon Pharmaceutical.
List of Exscientia patents
|US20210251995A1||Pyrazolopyrimidine compounds as adenosine receptor antagonists|
|EP2502173A2||Design of molecules|
|EP3802540A1||Pyrazolopyrimidine compounds as adenosine receptor antagonists|
|WO2019233994A1||Pyrazolopyrimidine compounds as adenosine receptor antagonists|
|JP2021526150A||Pyrazolopyrimidine compounds as adenosine receptor antagonists|
|CA3100923A1||Pyrazolopyrimidine compounds as adenosine receptor antagonists|
|AU2019282098A1||Pyrazolopyrimidine compounds as adenosine receptor antagonists|
|GB202109633D0||Drug optimisation by active learning|
|HK40040380A||Pyrazolopyrimidine compounds as adenosine receptor antagonists|
|GB202101703D0||Drug optimisation by active learning|
|BR112020024700A2||Pyrazolopyrimidine compounds as adenosine receptor antagonists|
|GB202018411D0||Malt-1 modulators i|
|GB202018412D0||Malt-1 modulators ii|
|GB202017177D0||Computational drug target selection|
|IN202047052525A||Pyrazolopyrimidine compounds as adenosine receptor antagonists|
|GB202016884D0||Drug optimisation by active learning|
|GB202011362D0||Antiviral compounds II|